Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy

3 février 2015 mis à jour par: Frank Lippert
The study will be randomized, investigator-blind, observer-blind, laboratory analyst-blind and will utilize a 5-way cross-over study design with a primary objective to determine if a higher dose of fluoride in milk will provide a greater caries preventive effect. Secondary objectives are to determine in a higher concentration of fluoride in milk will provide a greater caries preventive effect and if the caries preventive effect of fluoridated milk follows a dose-response pattern.

Aperçu de l'étude

Description détaillée

The evidence of milk fluoridation as a public health measure in caries prevention has been demonstrated in many clinical studies. While these data are encouraging, the main focus now should be on the optimization of milk fluoride programs. This protocol will concentrate on the parameters of fluoride dose and concentration utilizing an in situ model, the intra-oral caries test or model (ICT). The ICT is an established model which features the use of gauze-covered specimens to facilitate plaque growth and to simulate a caries-prone/plaque stagnation area. After subject has been consented and enrolled in the study per the inclusion/exclusion criteria, two to three days following a dental cleaning, two partially demineralized specimens will be placed in the buccal flange area of the subject's mandibular partial denture. During each of the five, three-week test periods, subjects will drink their assigned milk test product once per day for either five (100 ml milk) or ten (200 ml milk) timed minutes, wearing their mandibular partial dentures 24 hours a day during the test period. Fluoride free toothpaste will be used two to three days before and continuously during each treatment period. After each three-week test period, the two partially demineralized specimens will be removed from the subject's partial denture and analyzed using the surface microhardness test. Mineral content change (as percentage of surface microhardness recovery) in these artificially induced incipient enamel lesions will be the primary outcome variable. Each subject (n = 28) will serve as his or her own control.

Type d'étude

Interventionnel

Inscription (Réel)

28

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Indiana
      • Indianapolis, Indiana, États-Unis, 46202
        • Oral Health Research Institute, Indiana University School of Dentistry

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • sign an informed consent, authorization for the release of health information for research and provide medical history information, including medications, prior to their participation;
  • be between 18 and 80 years old and in general good health;
  • willingness to use a reliable form of contraception or abstaining during the course of the study (females of child-bearing potential only)
  • wear a removable mandibular partial denture with sufficient room in one posterior buccal flange area to accommodate two enamel specimens (required dimensions 12×7 mm);
  • be willing and capable of wearing their removable mandibular partial dentures 24 hours a day for a total of five, three-week test periods;
  • be in good dental health with no active caries or periodontal disease;
  • agree to comply with all subjects' responsibilities as stated in the protocol (e.g. use of study products, attendance at appointments, etc.);
  • have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 ml/min; gum base stimulated whole saliva flow rate ≥ 0.8 ml/min).
  • Be able to tolerate the taste and room temperature of the mixed milk product as demonstrated by drinking the milk at screening

Exclusion Criteria:

be pregnant, intending to become pregnant during the study period or breast feeding. A urine pregnancy test will be required at screening, the start of each treatment visit and the last study visit for all subjects of child-bearing potential to confirm the subject is not pregnant.

  • have any medical condition that could be expected to interfere with the subject's safety during the study period;
  • demonstrate an inability to comply with study procedures;
  • have factors which could contraindicate their participation, such as any condition requiring the need for antibiotic premedication prior to a dental treatment, a condition requiring the need for long-term antibiotic use, blood thinning medications that prohibit the safe conduct of a dental cleaning* or previous use of the weight loss medications Fen Phen® or Redux®. (*Note: Subjects who are taking blood thinners in which written verification is obtained from their physician indicating their PT/INR levels (anti-coagulation blood levels) are at an acceptable level to avoid serious complications, such as bleeding during dental cleanings, may be accepted into the study at the discretion of the Investigator.)
  • be currently taking or have ever taken a bisphosphonate drug (i.e. Fosamax®, Actonel®, Boniva®, Reclast®, or Zometa®) for treatment of osteoporosis.
  • be lactose intolerant or have known allergy or intolerance to milk or milk products

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Autre: Arm 1
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • Kroger Nonfat Dry Milk
Autre: Arm 2
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • Kroger Nonfat Dry Milk
Autre: Arm 3
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • Kroger Nonfat Dry Milk
Autre: Arm 4
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • Kroger Nonfat Dry Milk
Comparateur actif: Arm 5
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design
Autres noms:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Autres noms:
  • Kroger Nonfat Dry Milk

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
% Surface Microhardness (SMH) Recovery Score Per Each of Five Arms
Délai: Three Weeks per each of five arms
  • surface microhardness recovery is a measure of caries lesion remineralization and is calculated using the following equation:
  • SMHr=(D1-R)/(D1-B)×100 B = indentation length of sound enamel specimen at baseline D1 = indentation length after first in vitro demineralization R = indentation length after intra-oral exposure (rehardening).
Three Weeks per each of five arms

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
% Acid Resistance Score Per Each of Five Arms
Délai: Three Weeks per each of five arms
% Acid Resistance is a measure of acid resistance of the remineralized caries lesion which is calculated as (D1-D2)/(D1-B)*100%, where B is the indentation length of sound enamel specimen at baseline, D1 is an indentation length after first in vitro demineralization, D2 is an indentation length after second in vitro demineralization.
Three Weeks per each of five arms
Enamel Fluoride Uptake Per Each of Five Arms
Délai: Three Weeks per each of five arms
Enamel fluoride uptake is a measure of fluoridation of a caries lesion
Three Weeks per each of five arms

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Chercheur principal: Domenick Zero, DDS, MS, Indiana University

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 août 2012

Achèvement primaire (Réel)

1 avril 2013

Achèvement de l'étude (Réel)

1 juin 2013

Dates d'inscription aux études

Première soumission

7 août 2012

Première soumission répondant aux critères de contrôle qualité

13 août 2012

Première publication (Estimation)

16 août 2012

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

23 février 2015

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 février 2015

Dernière vérification

1 février 2015

Plus d'information

Termes liés à cette étude

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner